Email This Article

Headlines & Perspectives
Dyax, Cubist Ink R&D Deal for Blood-Loss Drug
By Elizabeth Trotta
04/24/08 - 01:16 PM EDT
Cubist will cover the development costs for an intravenous formulation of DX-88.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell
Submit Privacy Policy

Premium Stock Ideas
Find more premium investing ideas